1
|
Urakov A, Urakova N, Samorodov A, Shabanov P, Yagudin I, Stolyarenko A, Suntsova D, Muhutdinov N. Thermal imaging of local skin temperature as part of quality and safety assessment of injectable drugs. Heliyon 2024; 10:e23417. [PMID: 38192864 PMCID: PMC10771983 DOI: 10.1016/j.heliyon.2023.e23417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Revised: 12/02/2023] [Accepted: 12/04/2023] [Indexed: 01/10/2024] Open
Abstract
Injection of high-quality drugs can occasionally cause unexpected and unexplained local complications. As the current standard for drug quality control does not include an assessment of the local irritation effects of drugs, this effect may cause postinjection complications. Simultaneously, local irritation effects of the drugs can be assessed based on local tissue inflammation. The dynamics of local temperature can assess inflammation. Infrared monitoring of local skin temperature dynamics at subcutaneous, intramuscular, and intravenous injection sites of drugs under experimental and clinical conditions can improve their quality and safety. Therefore, there is a need to include dynamic thermography in the standard of biological evaluation of the quality and safety of drugs in the dosage form "solution for injections." This eliminates the local irritation and necrotizing activity of drugs and minimizes the development of local pain syndrome, aseptic inflammation, necrosis, and abscess.
Collapse
Affiliation(s)
- Aleksandr Urakov
- Department of General and Clinical Pharmacology, Izhevsk State Medical University, Izhevsk, Russia
- Department of Inventions and Patents, Institute of Thermology, Izhevsk, Russia
| | - Natalya Urakova
- Department of General and Clinical Pharmacology, Izhevsk State Medical University, Izhevsk, Russia
- Department of Inventions and Patents, Institute of Thermology, Izhevsk, Russia
| | | | - Petr Shabanov
- Department of Neuropharmacology, Institute of Experimental Medicine, Saint Petersburg, Russia
| | - Ilnur Yagudin
- Department of General and Clinical Pharmacology, Izhevsk State Medical University, Izhevsk, Russia
| | - Anastasia Stolyarenko
- Department of General and Clinical Pharmacology, Izhevsk State Medical University, Izhevsk, Russia
| | - Darya Suntsova
- Department of General and Clinical Pharmacology, Izhevsk State Medical University, Izhevsk, Russia
| | - Nikita Muhutdinov
- Department of General and Clinical Pharmacology, Izhevsk State Medical University, Izhevsk, Russia
| |
Collapse
|
2
|
Fekete GL, Iantovics LB, Fekete JE, Fekete L. Embolia cutis Medicamentosa (Nicolau syndrome): case series. Front Med (Lausanne) 2023; 10:1216781. [PMID: 38020151 PMCID: PMC10653301 DOI: 10.3389/fmed.2023.1216781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Accepted: 09/18/2023] [Indexed: 12/01/2023] Open
Abstract
Introduction Embolia cutis medicamentosa or Nicolau syndrome is a rare drug reaction associated with the administration of various injectable medications. The pathogenesis of the disease is unknown, though intra and periarterial injection of the drug is a possible cause. The aim of this study was to describe and analyze the clinical characteristics of Nicolau syndrome in patients examined in daily dermatological practice. Methods We performed a retrospective chart review, between January 2011 and December 2020, in patients diagnosed with Nicolau syndrome, from the cases of a private dermatology medical office in Târgu Mureș, Romania. Results During the 10-year period, 7 patients were diagnosed with Nicolau syndrome. Of these, 4 (57%) patients were males and 3 (43%) were females, The male to female ratio was 1.33. The median age was 64 (interquartile range, IQR, 62-71), with the youngest patient being diagnosed at age 61 and the oldest at age 74. Regarding the drugs classes that caused Nicolau syndrome, these were intravenous antibiotics in 57%, and non-steroidal anti-inflammatory drugs in 43% of cases. Conclusion All patients healed in a period of 6 to 8 weeks. No complications occurred. In conclusion, Nicolau syndrome is a rare side effect of injectable drug administration.
Collapse
Affiliation(s)
- Gyula Laszlo Fekete
- Department of Dermatology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, Targu Mures, Romania
- CMI Dermamed Private Medical Office, Targu Mures, Romania
| | - Laszlo Barna Iantovics
- Department of Electrical Engineering and Information Technology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, Targu Mures, Romania
| | - Júlia Edit Fekete
- National Institute of Public Health, Regional Center for Public Health, Targu Mures, Romania
| | - Laszlo Fekete
- CMI Dermamed Private Medical Office, Targu Mures, Romania
- Doctoral School, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, Targu Mures, Romania
| |
Collapse
|
3
|
Plachouri KM, Georgiou S. Mesotherapy: Safety profile and management of complications. J Cosmet Dermatol 2019; 18:1601-1605. [PMID: 31444843 DOI: 10.1111/jocd.13115] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Revised: 06/20/2019] [Accepted: 08/01/2019] [Indexed: 01/23/2023]
Abstract
BACKGROUND Mesotherapy is a procedure that involves the injection of active substances into the dermis and subcutaneous tissue in order to treat several local medical and cosmetic conditions. Despite being considered as a relatively safe method, a series of adverse reactions can occur due to its wide application and lack of standardization processes. OBJECTIVES The aim of this paper is to summarize all the mesotherapy-related complications published so far, and to provide an insight into their management. PATIENT/METHODS Articles derived from the databases, PubMed, EMBASE, and SCOPUS, and published between 1992 and 2018, were analyzed for this review. The study was conducted according to the PRISMA guidelines. RESULTS In this literature, there is a number of case series and isolated case reports describing various side effects of different severities. The therapeutic management of these complications is-in most cases-individualized. CONCLUSIONS Larger systematic studies are needed in order to adequately evaluate the safety profile of mesotherapy, and in order to determine standardized therapy parameters, so as to minimize the risk of potential adverse reactions.
Collapse
Affiliation(s)
| | - Sophia Georgiou
- Dermatology Department, University of Patras, Patras, Greece
| |
Collapse
|
4
|
Kim KK, Chae DS. Nicolau syndrome: A literature review. World J Dermatol 2015; 4:103-107. [DOI: 10.5314/wjd.v4.i2.103] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2014] [Revised: 12/20/2014] [Accepted: 03/20/2015] [Indexed: 02/06/2023] Open
Abstract
Nicolau syndrome (NS) is a rare cutaneous adverse reaction after intra-muscular or intra-articular injection. Clinical features of NS are presented by three typical phases (initial, acute and necrotic phases). The cause of NS is acute vasospasm, inflammation of arteries and thromboembolic occlusion of arteriole related various drugs. Many results of laboratory test, imaging studies and histopathology are reported and are associated with disease status. Three phase treatment is recommended for the patients with NS. Initially pain control and rule out differential diagnosis and in acute phase steroid therapy, heparin and pentoxifylline are useful. In necrotic phase, surgical treatment is needed depending on size of the affected site. NS is not well understood so far, however three phase treatment could lead to good result on basis of literature review.
Collapse
|
5
|
Bouquié R, Wainstein L, Pilet P, Mussini JM, Deslandes G, Clouet J, Dailly E, Jolliet P, Victorri-Vigneau C. Crushed and injected buprenorphine tablets: characteristics of princeps and generic solutions. PLoS One 2014; 9:e113991. [PMID: 25474108 PMCID: PMC4256378 DOI: 10.1371/journal.pone.0113991] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2014] [Accepted: 11/02/2014] [Indexed: 02/07/2023] Open
Abstract
Self-injection of high-dose buprenorphine is responsible for well-described complications. In 2011, we have been alerted by unusual but serious cutaneous complication among injection buprenorphine users. A prospective data collection identified 30 cases of necrotic cutaneous lesions after injection of filtered buprenorphine solution, among which 25 cases occurred following injection of buprenorphine generics. The main goal of our study was to put forward particularities that could explain the cutaneous complications, by qualitatively and quantitatively confronting particles present in Subutex and generics solutions. We used the same protocol that injected-buprenorphine users: generic or subutex tablets were crushed in sterile water and filtered through 2 filters commonly used (cotton-pad and sterifilt). Solutions were analyzed by laser granulometry, flow cytometry and scanning electron microscopy. We have highlighted the wide variation of the quantity and the size of the particles present in solution between the two drugs after cotton-pad filtration. The proportion of particles <10 µm is systematically higher in the generic solutions than with Subutex. All of the insoluble particles found in generic solutions contain silica, whereas non- organic element was to be identified in the insoluble particles of Subutex. One skin biopsy obtained from one patient who developed a necrotic lesion after intravenous injection of filtrated solution of buprenorphine generic, shows non-organic elements. Identification of particles in situ enables us to confirm the presence of silica in the biopsy. Actually the monitoring of patient receiving generic of buprenorphine must be strengthened.
Collapse
Affiliation(s)
- Régis Bouquié
- Service de Pharmacologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France
- EA 4275 Biostatistique, Pharmacoépidémiologie et Mesures Subjectives en Santé, Université de Nantes, Nantes, France
- * E-mail:
| | - Laura Wainstein
- Service de Pharmacologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France
| | - Paul Pilet
- INSERM (Institut National de la Santé et de la Recherche Médicale), UMR (Unité Mixte de Recherche) 791, Laboratoire d’Ingénierie Ostéo-Articulaire et Dentaire (LIOAD), Université de Nantes, Nantes, France
- Centre Hospitalier Universitaire de Nantes, Pôle Hospitalo-Universitaire 4, Nantes, France
| | - Jean-Marie Mussini
- Laboratoire d'Anatomie Pathologique, Centre Hospitalier Universitaire de Nantes, Nantes, France
| | - Guillaume Deslandes
- Service de Pharmacologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France
| | - Johann Clouet
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche en Santé (UMRS) 791, Laboratoire d’Ingénierie Ostéo-Articulaire et Dentaire (LIOAD), Université de Nantes, Nantes, France
- Centre Hospitalier Universitaire Nantes, Pôle Hospitalo-Universitaire (PHU) 7, Pharmacie Centrale, Nantes, France
| | - Eric Dailly
- Clinical Pharmacology, Service de Pharmacologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France
- EA 3826 Thérapeutiques Cliniques et Expérimentales des Infections, Université de Nantes, Nantes, France
| | - Pascale Jolliet
- EA 4275 Biostatistique, Pharmacoépidémiologie et Mesures Subjectives en Santé, Université de Nantes, Nantes, France
- Clinical Pharmacology, Service de Pharmacologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France
| | - Caroline Victorri-Vigneau
- EA 4275 Biostatistique, Pharmacoépidémiologie et Mesures Subjectives en Santé, Université de Nantes, Nantes, France
- Pharmacology, Service de Pharmacologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France
| |
Collapse
|